Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025597 | 0.86 | PPARA (0.34) | CA12CA1CA9PPARAHSD11B1 | |
| SCHEMBL17049520 | 0.86 | LMNA (0.33) | PPARGPPARACHRM1DRD2DRD4 | |
| SCHEMBL3029917 | 0.82 | — | — | |
| SCHEMBL17026898 | 0.81 | CA1 (0.33) | CA1CA9PPARGPPARAALDH1A1 | |
| SCHEMBL14666735 | 0.80 | RARA (0.33) | LMNAALDH1A1CNR2 | |
| SCHEMBL17026999 | 0.79 | PPARG (0.36) | CA1CA9PPARGPPARA | |
| SCHEMBL17141512 | 0.79 | PREP (0.36) | CA12CA1CA9HSD11B1CHRM1 | |
| SCHEMBL12049961 | 0.77 | SCD5 (0.36) | — | |
| SCHEMBL14162088 | 0.76 | CHRM1 (0.35) | CHRM1DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL27788934 | 0.76 | PPARA (0.43) | CA1PPARGPPARAHSD11B1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137415-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| EP-2179994-B1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2179994-A1 | FUSED BICYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | CA12 2422/4885CA1 1919/4885CA9 1917/4885 |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | CA12 2031/4885CA1 1638/4885CA9 1607/4885 |
| US-20170137415-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS | SCN7A, SCN1A, SCN5A | CA12 2582/4885CA1 1735/4885CA9 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.